On September 24, Jingtai Technology announced that its self-developed gut-restrictive highly selective Pan-TRK inhibitor KQTD-126 has completed pre-clinical research and submitted a new drug clinical trial application to the US Food and Drug Administration. This inhibitor is mainly used to treat chronic intestinal pain associated with irritable bowel syndrome and inflammatory bowel disease.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.